Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin‐like growth factors and IGF binding proteins 1 and 3: a cross‐over study
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE Conflicting results have been reported on the effects of oral and transdermal oestrogen replacement therapy on IGF‐I, while little information exists regarding the effects on IGFBP ‐1 and ‐3. In this study we evaluated the effects of oral and transdermal oestrogens on these parameters in post‐menopausal women in a randomized cross‐over study. PATIENTS A group of 14 post‐menopausal women were randomized to receive progestin‐opposed oestrogen replacement therapy administered orally (Trisekvens Novo: 17β‐oestradiol 2 mg daily on days 1–22 and 1 mg daily on days 23–28, norethisterone 1 mg days 13–22) or transdermally (Estracomb CIBA: oestradiol 50 μg/24 h on days 1–28, norethisterone 250 μg/24 h on days 15–28) for 6 months after which they were crossed over to the alternative treatment option. Fasting blood samples were obtained before treatment, and after 3, 6, 9 and 12 months on treatment. MEASUREMENTS IGF‐I, IGF‐II, IGFBP‐1, IGFBP‐3, oestradiol and norethisterone were analysed by radioimmunoassays. In addition, IGFBPs were evaluated with Western ligand blots (WLB) in a subgroup of 12 patients. RESULTS Plasma levels of oestradiol were not significantly different during oral and transdermal treatment. Norethisterone levels were below the detection limit in all situations in 8 patients, while 6 patients had detectable levels in one or several samples during treatment. Oral treatment caused a significant decrease (16%, P<0.005) in IGF‐I and a non‐significant decrease in IGFBP‐3. A similar effect was observed when samples containing detectable levels of norethisterone were excluded from the analysis. No significant effect on IGFBP‐1 was observed when all samples were included in the analysis. However, when samples with detectable norethisterone were excluded IGFBP‐1 increased by 46% (P<0.01) during oral therapy. Contrary, transdermal treatment with oestrogens did not influence any of the parameters measured. None of the treatments had any effect on plasma IGF‐II levels or IGFBP profile evaluated by WLB. CONCLUSIONS Treatment with oral hormone replacement therapy significantly suppresses plasma IGF‐I levels and increases plasma IGFBP‐1 while transdermal treatment had no influence. This may be due to the route of administration, as plasma oestradiol levels showed little difference between the groups. The effect of oral oestrogens on IGFBP‐1 seems to be attenuated by progestins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WEISSBERGER, A. J., HO, K. K. Y., & LAZARUS, L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-2-374 · Cited by 514
Cited by
Understanding weight gain at menopause
Davis, S. R., Castelo-Branco, C., Chedraui, P., Lumsden, M. A., Nappi, R. E., Shah, D., Villaseca, P., & as the Writing Group of the International Menopause Society for World Menopause Day 2012 (2012) · Climacteric · doi:10.3109/13697137.2012.707385 · Cited by 604
Estrogen Regulation of Growth Hormone Action
Leung, K.-C., Johannsson, G., Leong, G. M., & Ho, K. K. Y. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0035 · Cited by 542
A Polymorphism in the Gene for IGF-I
Vaessen, N., Heutink, P., Janssen, J. A., Witteman, J. C. M., Testers, L., Hofman, A., Lamberts, S. W. J., Oostra, B. A., Pols, H. A. P., & van Duijn, C. M. (2001) · Diabetes · doi:10.2337/diabetes.50.3.637 · Cited by 354
Lukanova, A., Lundin, E., Zeleniuch-Jacquotte, A., Muti, P., Mure, A., Rinaldi, S., Dossus, L., Micheli, A., Arslan, A., Lenner, P., et al. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500161 · Cited by 315
The impact of dose and route of estrogen administration on the somatotropic axis in normal women.
Lissett, C. A., & Shalet, S. M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-022036 · Cited by 48
Metadata
- Authors
- Helle, S. I., Omsjø, I. H., Cwyfan Hughes, S. C., Botta, L., Hüls, G., Holly, J. M. P., & Lønning, P. E.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 1996-12
- Volume
- 45
- Issue
- 6
- Pages
- 727-732
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2143580269
- Cited by
- 86
- References
- 1
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin‐like growth factors and IGF binding proteins 1 and 3: a cross‐over study. https://app.cochat.ai/papers/10.1046/j.1365-2265.1996.8610870.x
- The paper
- Helle, S. I., Omsjø, I. H., Cwyfan Hughes, S. C., Botta, L., Hüls, G., Holly, J. M. P., & Lønning, P. E. (1996). Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin‐like growth factors and IGF binding proteins 1 and 3: a cross‐over study. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.1996.8610870.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.